{"title":"对“伊鲁替尼联合利妥昔单抗和来那度胺治疗未经治疗的滤泡性和边缘区淋巴瘤的安全性和有效性：一项开放标签的2期研究”的更正","authors":"","doi":"10.1002/cncr.35933","DOIUrl":null,"url":null,"abstract":"<p>Gordon MJ, Feng L, Strati P, et al. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: an open label, phase 2 study. <i>Cancer</i>. 2024; 130(6): 876-885. https://doi.org/10.1002/cncr.35114</p><p>This correction is issued to add an acknowledgement of funding support and the associated Grant ID from research conducted in the original publication. The added acknowledgement is as follows: Christopher R. Flowers received support from the Cancer Prevention and Research Institute of Texas (RR190079), where he is a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research.</p><p>We apologize for this error.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 12","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35933","citationCount":"0","resultStr":"{\"title\":\"Correction to “Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study”\",\"authors\":\"\",\"doi\":\"10.1002/cncr.35933\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Gordon MJ, Feng L, Strati P, et al. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: an open label, phase 2 study. <i>Cancer</i>. 2024; 130(6): 876-885. https://doi.org/10.1002/cncr.35114</p><p>This correction is issued to add an acknowledgement of funding support and the associated Grant ID from research conducted in the original publication. The added acknowledgement is as follows: Christopher R. Flowers received support from the Cancer Prevention and Research Institute of Texas (RR190079), where he is a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":138,\"journal\":{\"name\":\"Cancer\",\"volume\":\"131 12\",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35933\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35933\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35933","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
Gordon MJ, Feng L, Strati P，等。依鲁替尼联合利妥昔单抗和来那度胺治疗未经治疗的滤泡性和边缘区淋巴瘤的安全性和有效性：一项开放标签的2期研究癌症。2024;130(6): 876 - 885。发布https://doi.org/10.1002/cncr.35114This更正，以添加对原始出版物中进行的研究的资金支持和相关赠款ID的确认。额外的致谢如下：Christopher R. Flowers得到了德克萨斯州癌症预防与研究所（RR190079）的支持，他是德克萨斯州癌症预防与研究所的癌症研究学者。我们为这个错误道歉。
Correction to “Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study”
Gordon MJ, Feng L, Strati P, et al. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: an open label, phase 2 study. Cancer. 2024; 130(6): 876-885. https://doi.org/10.1002/cncr.35114
This correction is issued to add an acknowledgement of funding support and the associated Grant ID from research conducted in the original publication. The added acknowledgement is as follows: Christopher R. Flowers received support from the Cancer Prevention and Research Institute of Texas (RR190079), where he is a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research.
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
